Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

1 Disparities in SARS-CoV-2 exposure: evidence from a citywide

2 seroprevalence study in Holyoke, Massachusetts, USA

- 3 Running title: SARS-CoV-2 Antibodies in Holyoke, MA
- 4
- 5 Wilfredo R. Matias^{123*}, Isabel R. Fulcher^{45*}, Sara M. Sauer⁴, Cody P. Nolan⁶, Yodeline
- 6 Guillaume³, Jack Zhu³, Francisco J. Molano³, Elizabeth Uceta³, Shannon Collins³, Damien M.
- 7 Slater¹, Vanessa M. Sánchez¹, Serina Moheed¹, Jason B. Harris¹⁷, Richelle C. Charles¹⁸, Ryan M.
- 8 Paxton⁹, Sean F. Gonsalves⁹, Molly F. Franke⁴, Louise C. Ivers¹³⁴
- 9
- ¹Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA
- 11 ²Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA
- ³Center for Global Health, Massachusetts General Hospital, Boston, MA
- ⁴Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA;
- 14 ⁵Harvard Data Science Initiative, Cambridge, MA
- 15 ⁶Department of Medicine, Brigham and Women's Hospital, Boston, MA
- ⁷Department of Pediatrics, Harvard Medical School, Boston, MA
- 17 ⁸Department of Medicine, Harvard Medical School, Boston, MA
- ⁹Holyoke Board of Health, Holyoke, MA
- 19 *Contributed equally.
- 20
- 21 Corresponding author:
- 22 Wilfredo R. Matias, MD MPH
- 23 Massachusetts General Hospital
- 24 Division of Infectious Diseases
- 25 55 Fruit St, BUL-130, Boston MA 02114
- 26 1-(857)-207-1584
- 27 wmatias@bwh.harvard.edu
- 28
- 29 Abstract (long) word count: 325
- 30 Manuscript word count: 3497
- 31 Figures: 2
- 32 Tables: 4
- 33
- 34 Key words: SARS-CoV-2; COVID-19; seroprevalence; serosurvey; serological survey;
- 35 antibodies; Holyoke

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

36 Abstract

Background: Seroprevalence studies are important tools to estimate the prevalence of prior or
recent SARS-CoV-2 infections, identifying hotspots and high-risk groups and informing public
health responses to the COVID-19 pandemic. We conducted a city-level seroprevalence study in
Holyoke, Massachusetts, USA to estimate the seroprevalence of SARS-CoV-2 antibodies and
risk factors for seropositivity.

42

43 *Methods:* We invited inhabitants of 2,000 randomly sampled addresses between November 5 44 and December 31, 2020. Participants completed questionnaires measuring sociodemographic and 45 health characteristics, and COVID-19 exposure history, and provided dried blood spots for 46 measurement of SARS-CoV-2 IgG and IgM antibodies. We calculate total and subgroup 47 seroprevalence estimates based on presence of IgG antibodies using a Bayesian procedure that 48 incorporates uncertainty in antibody test sensitivity and specificity. We account for clustering by 49 household and weighting based on demographic characteristics to ensure estimates represented 50 the city's population.

51

52 Findings: We enrolled 280 households including 472 individuals. 328 underwent antibody 53 testing. The citywide seroprevalence estimate of SARS-CoV-2 IgG was 13.1% (95%CI 6.9-22.3) 54 compared to 9.8% based on publicly reported case counts. Seroprevalence was 16.1% (95%CI 55 6.2-31.8) among individuals identifying as Hispanic compared to 9.4% (95%CI 4.6-16.4) among 56 those identifying as non-Hispanic white. Seroprevalence was higher among Spanish speaking 57 households (21.9%; 95% CI 8.3-43.9) compared to English speaking households (10.2%; 95% 58 CI 5.2-18.0) and among individuals living in high vulnerability areas (14.4%; 95% CI 7.1-25.5) 59 compared to low vulnerability areas (8.2%; 95% CI 3.1-16.9).

60

Interpretation: The measured SARS-CoV-2 seroprevalence of IgG antibodies in Holyoke was only 13.1% during the second surge of SARS-CoV-2 in this region, far from accepted thresholds for "herd immunity." Already vulnerable communities were at highest risk of prior infection. Implementation of local serosurveys in tandem with proactive public health interventions that address disparities in SARS-CoV-2 exposure are crucial to ensure at-risk communities have appropriate educational materials and access to vaccines, testing, and timely treatment.

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

67

- 68 *Funding*: The Sullivan Family Foundation, Harvard Data Science Institute Bias² program, the
- 69 US Centers for Disease Control and Prevention.

70

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

72 **Research in context**

73 Evidence before this study

74 The implementation of our seroepidemiologic study in Holyoke, Massachusetts December 2020 75 was informed by both the (1) variation in SARS-CoV-2 seroprevalence from surrounding 76 communities and (2) lack of information on risk of SARS-CoV-2 infection by race and ethnicity 77 status. Specifically, a serosurvey using convenience sampling of asymptomatic individuals in the 78 predominantly Hispanic community of Chelsea, MA, during April 2020 demonstrated a high 79 seroprevalence of 31.5%. This serosurvey was limited by non-representative convenience 80 sampling that likely resulted in a biased estimate in addition to the use of a rapid lateral flow 81 immunoassay with imperfect test accuracy. In July and August 2020, a university-related 82 population and their household members in Massachusetts demonstrated a much lower 83 seroprevalence between 4-5.3%. To our knowledge, these were the only two seroepidemiologic 84 surveys in searchable databases at the time of this study. Globally, a recent systematic review 85 and meta-analysis of SARS-CoV-2 serosurveys through December 2020 demonstrated 86 significant regional variability in seroprevalence estimates and associated risk factors and highlighted similar methodological constraints as described above. Thus, our goal was to conduct 87 88 a local serosurvey with the aim of informing community-tailored public health responses for at-89 risk groups, using population-representative sampling methods, and accounting for uncertainty in

- 90 test performance characteristics.
- 91

92 Added value of this study

93 We found that the seroprevalence of SARS-CoV-2 IgG antibodies was 13.1% during the second 94 wave, far from acceptable levels of herd immunity, but also discrepant from the COVID-19 95 testing data from the city, which reported a prevalence of 9.6%. Hispanic and Latino/a 96 individuals, individuals from Spanish-speaking households, and individuals living in areas with a 97 high social vulnerability index had higher seroprevalence of SARS-CoV-2 IgG antibodies, 98 indicating that already vulnerable communities were at a higher risk of prior infection. We 99 utilized a novel Bayesian analytic approach to account for the sensitivity and specificity of the 100 antibody test, while ensuring our study population reflected the population of Holyoke.

101

102 Implications of all the available evidence

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

- 103 Our findings highlight the need for wide implementation of population-representative local
- 104 serosurveys to ensure local details are not masked by findings at the state and national levels. In
- 105 tandem with locally implemented serosurveys, proactive public health interventions will be
- 106 crucial to respond to disparities in infection risk that will likely continue to propagate in the
- 107 absence of further interventions.

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

1	Λ	n
1	υ	У

110 Background

111 Due to limitations in access to testing or because of the high frequency of asymptomatic 112 infections, official reports have underestimated actual infection rates with severe acute 113 respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 114 2019 (COVID-19), leaving public health officials with an incomplete picture of viral spread and 115 associated risk factors.^{1,2} To address these limitations, seroepidemiologic prevalence studies (serosurveys) which measure the presence of anti-SARS-CoV-2 antibodies as a marker of prior 116 117 infection have become an important public health tool to estimate incidence, identify risk factors and guide public health responses.³ 118 119 120 A recent systematic review and meta-analysis of SARS-CoV-2 serosurveys through December 121 2020 demonstrated significant regional variability in seroprevalence estimates and associated 122 risk factors.³ This reflects findings in the United States (US), where a national serosurvey across 123 10 sites during the first surge in 2020 documented a seroprevalence ranging between 1.0% in the 124 San Francisco Bay area and 6.9% in New York City.⁴ In addition to regional variability, most SARS-CoV-2 serosurveys have suffered from several methodological constraints, predominantly 125 126 related to non-representative sampling protocols and inaccuracies in serologic assays. 127 128 In the US, the Commonwealth of Massachusetts (MA), fueled by a super-spreader event of 129 SARS-CoV-2, became one of the early epicenters of the pandemic.⁵ Variable local pandemic 130 dynamics necessitate locally tailored responses, highlighting the importance of conducting local 131 surveys to guide local public health responses to the SARS-CoV-2 pandemic.³ 132 133 Holyoke is a post-industrial, majority Hispanic/Latino/Latina city in MA with high levels of 134 socio-economic disadvantage. Based on 2018 census data, the poverty rate and median 135 household income were 29.7% and \$40,656, respectively, compared to 10.8% and \$79,835 for 136 MA.⁶ The city was disproportionately affected by the first surge of COVID-19 as evidenced by a high initial case count relative to the rest of the commonwealth.^{7,8} To fill the gap in our 137 138 knowledge of city-level seroprevalence in the US and inform local public health responses, we 139 conducted a serosurvey of the city of Holyoke, MA, during the second surge of SARS-CoV-2

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

- 140 cases between November and January 2021. Measurement of antibodies against SARS-CoV-2
- 141 was paired with questionnaires to identify household and individual-level risk factors associated
- 142 with prior infection with SARS-CoV-2.
- 143
- 144

145 Methods

- 146 Study Design and Sampling
- 147 We conducted a representative, cross-sectional household-based seroepidemiologic SARS-CoV-
- 148 2 survey in the City of Holyoke, MA. We obtained an official list of the 17,828 addresses in the
- 149 city's 11 census tracts from the city records. We identified and removed listings corresponding to
- 150 congregate living facilities, vacant buildings, duplicate entries, and empty listings. The
- remaining addresses were considered eligible for sampling. We then randomly sampled 2,000
- addresses from this final list.
- 153

154 Participant Recruitment

Participants were enrolled from November 5, 2020, through December 31, 2020. The study team 155 156 mailed an invitation letter to sampled addresses that contained a QR code and a unique ID for an 157 online survey hosted on REDCap (Research Electronic Data Capture) at Massachusetts General 158 Hospital. Among selected addresses, all individual household members aged ≥ 6 months and 159 residing at the address were eligible for enrollment. A household was defined as a group of 160 persons who slept under the same roof most nights. Households were given a period of 161 approximately five days to respond by either taking the online survey or contacting the study 162 team. Households could opt-out of future communication by calling a phone number. Following 163 that period, data collectors made reminder follow-up calls, where participants had the option of 164 completing the survey over the phone, and conducted home visits to follow-up with households 165 that lacked a telephone number, were unresponsive to calls, or requested a visit from the team. 166 To raise awareness about the study and increase community engagement, the study team 167 distributed fliers and made announcements via Facebook and local media in both English and 168 Spanish.

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

170 Following the first month of recruitment, we mailed a second wave of invitation letters to the

171 originally sampled households, excluding ineligible addresses and households that had either

already completed their surveys or opted out of the study. Data collectors made follow-up phone

173 calls to households with incomplete surveys and those who had not mailed back their samples.

174

175 Data Collection

176 The survey tool consisted of an eligibility and informed consent form, one household-level

survey, and individual adult and child surveys for each consenting adult and child household

178 member. Surveys included questions regarding sociodemographic characteristics, occupation and

179 employment history, clinical history, symptoms, and COVID-19 testing, and exposure history.

180 Upon completion of these surveys, blood test kits were either mailed to participant addresses or

181 physically provided during home visits. We provided a \$25 gift card to each household in which

182 at least one person completed the entire study.

183

184 Sample Collection, Transportation and Laboratory Testing

185 Test kits contained supplies and instructions (in English and Spanish) for self-collection of dried

186 blood spot (DBS) samples. Individuals were instructed to perform a pinprick on the finger using

187 a lancet and applying it to Whatman[®] Protein Saver 903 filter paper collection cards

188 (https://www.cytivalifesciences.com). Once obtained, samples were return mailed using a

189 preaddressed envelope to Massachusetts General Hospital (Boston, MA, USA) where they were

190 stored at -20°C with desiccant until tested. DBS sampling has been validated for use in antibody

191 testing of SARS-CoV-2 and other pathogens.^{9,10}

192

193 DBS were eluted and tested for the presence of SARS-CoV-2 IgG and IgM receptor-binding

194 domain of the spike protein of SARS-CoV-2 using a quantitative ELISA previously developed

and validated using reverse transcriptase polymerase chain reaction (RT-PCR)-positive mild and

196 severe SARS-CoV-2 infections and pre-pandemic samples at Massachusetts General Hospital.^{11–}

¹³ The test specificity and sensitivity estimates were respectively 99.5% (95% CI 99.0-99.8) and

198 70.6% (95% CI 61.2-79.3%) for IgG antibodies and were calculated using samples from the

199 Boston area. Further details provided in Section 2 of the Supplementary Materials.

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

201 Statistical Analysis

202 Our main SARS-CoV-2 seroprevalence estimate was the proportion of the population that had

203 IgG antibodies detected as this aligns with prior studies. We also calculated seroprevalence

204 estimates with corresponding 95% credible intervals for the following combinations of IgG and

IgM antibody positivity: IgG or IgM, IgG only, IgM, and IgM only.

206

207 We used a modified version of the Bayesian procedure proposed by Stringhini et al.¹⁴ to

208 calculate prevalence estimates with corresponding 95% credible intervals. The procedure

accounted for uncertainty in the antibody test sensitivity and specificity. Within the procedure, a

210 random intercept was used to account for clustering by household and weighting was applied to

211 ensure the seroprevalence estimates were representative of the population of the City of Holyoke.

212 Details on the procedure are provided in Section 1 of the Supplementary Materials.

213

A raking procedure was used to construct weights based on the distribution of age, race and

ethnicity, gender, and census tract in the City of Holyoke from the 2019 American Community

216 Survey (ACS) (Table 1). Notably, gender is reported as the percent of "Female persons" in

217 Holyoke in the ACS survey results, such that we only have two categories for gender: Female

and non-Female, which includes male, transgender, and non-binary persons. For the purposes of

219 constructing weights, we collapsed sparse categories of race and ethnicity into a "Grouped

220 category". The census tracts were also collapsed into "high vulnerability" and "low

221 vulnerability" groups based on the social vulnerability index (SVI).¹⁵ High vulnerability was

222 defined as having an SVI greater than the 75^{th} percentile of census tracts in Massachusetts – 9 of

the 11 census tracts were considered high.

224

225 We compare seroprevalence estimates and 95% credible intervals (CI) across subgroups. To

226 investigate disparities in known risk factors for SARS-CoV-2 infection, we report

sociodemographic and clinical factors stratified by race/ethnicity. Analyses were conducted in R

228 V4.0.0 using *survey* and *rstan* packages.¹⁶

229

230 Ethics

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

- 231 Informed consent was obtained from adults 18 years or older. Informed parental consent and
- assent was obtained for children ages 14 17. Parental consent was obtained for children under
- the age of 14, with documented verbal assent by the caregiver sought for minors between the
- ages of 7 13. This protocol was reviewed by the Mass General Brigham Human Research
- 235 Committee Institutional Review Board (Protocol ID: 2020P002560, November 2nd, 2020).
- 236

237 Results

238 Study population

- From the final list of 17,204 addresses, we randomly sampled 2,000 and mailed invitation letters
- and followed up recruitment as described above. 280 households (14%) with 472 individuals
- agreed to participate and completed household and individual-level questionnaires. Figure 1
- 242 demonstrates a complete flow diagram of participant progress through study phases. Mean
- household size was 2.28 individuals (SD: 1.2). Within participating households, an average mean
- of 1.77 household members (SD 1.03) consented to participate. Of these, 197 households
- 245 (70.4%), 330 individuals (69.9%) completed and returned a DBS sample for analysis. A total of
- 246 328 samples from 195 households were analyzed. The mean household size for households with
- individuals that provided a DBS sample and were analyzed was 2.09 individuals (SD: 1.13), and
- the mean number of individuals per household that consented to participate was 1.71 (SD 0.96).
- 249

Among the 280 households that completed the survey, 37 reported hospitalization of a household

- 251 member since February 2020 (13.3%, 1 missing response). Only one of these hospitalizations
- was reported to be a result of COVID-19. There were 2 reported deaths amongst the households
- since February 2020 among 277 households (3 missing responses). 25 of 471 respondents
- 254 (5.31%, 1 missing response) described being diagnosed by a healthcare provider with pneumonia
- or other respiratory infection (may include COVID-19 diagnosis) since February 2020. 20 of the
- 468 respondents (4.3%, 4 missing response) reported testing positive for COVID-19 at least
- 257 once.

258

Demographic characteristics including gender, age group and race/ethnicity breakdown for the
 entire study population is listed in Table 1. Individuals from younger age groups and individuals

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

261 identifying as Hispanic or Latino/Latina were underrepresented in the study population relative

- to the population of Holyoke.
- 263
- 264 Citywide Seroprevalence of SARS-CoV-2 Antibodies
- 265 Of 328 individual samples tested, 27 individuals from 20 households were positive for SARS-
- 266 CoV-2 IgG or IgM antibodies; after adjusting for clustering, differential response rates and
- 267 imperfect test sensitivity, this corresponded to a citywide seroprevalence estimate of 13.6%
- 268 (95%CI: 6.7-23.7). 25 individuals were positive for SARS-CoV-2 IgG antibodies, corresponding
- to an adjusted citywide seroprevalence estimate of 13.1% (6.9-22.3%). Seroprevalence estimates
- 270 for individuals with IgG only, IgM only, and IgG and IgM are listed in Table 2. In the
- 271 Supplemental Materials, we provide seroprevalence estimates under various sensitivity estimates
- ranging from 60.2% to 78.8%, corresponding to overall IgG seroprevalence estimates ranging
- 273 from 15.3% to 11.7%, respectively.
- 274

275 Seroprevalence of SARS-CoV-2 Antibodies by Sociodemographic Characteristics

276 Seroprevalence estimates were calculated for the following subgroups: age groups, gender,

277 race/ethnicity, social vulnerability index, primary language spoken in the household, and other

278 sociodemographic characteristics listed in Table 3. Seropositivity varied across multiple

subgroups, though confidence intervals tended to be wide. The seroprevalence estimate was

highest among individuals 20-44 years old (17.6%; 95%CI 7.5-32.4) and decreased with age.

Likewise, the seroprevalence estimate was higher at 16.1% (95%CI: 6.2-31.8) among individuals

282 identifying as Hispanic or Latino/Latina compared to a seroprevalence estimate of 9.4% (95%CI:

283 4.6-16.4) among individuals identifying as white. The seroprevalence estimate among Spanish

284 speaking households was 21.9% (95% CI 8.3-43.9) compared to 10.2% (95% CI 5.2-18.0)

among English speaking households. Individuals living in high vulnerability areas (14.4%; 95%

286 CI 7.1-25.5) had a higher seroprevalence estimate than individuals living in low vulnerability

287 areas (8.2%; 95% CI 3.1-16.9).

288

289 Seroprevalence of SARS-CoV-2 Antibodies by Medical, Symptom and Exposure History

290 We investigated seroprevalence by medical conditions and COVID-19 symptoms, testing, and

291 exposure history (Figure 2). Notably, the seroprevalence estimate of individuals reporting any of

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

- the listed symptoms since February 2020 was 18.6% (95% CI 9.6-31.4) compared to a
- seroprevalence of 5.6% (95% CI: 1.0-15.3) among individuals reporting no symptoms since that
- time. There was also variation in seroprevalence estimate by the type of exposure to individuals
- with confirmed COVID-19. The seroprevalence among individuals reporting an exposure to a
- 296 household member was 72.4% (95%CI: 32.6-99.7), while only 21.3% (95%CI: 8.0-41.5%)
- among those reporting an exposure to a non-household member and 5.8% (95%CI: 1.9-13.4%)
- among those reporting no known exposure to someone with COVID-19.
- 299
- 300 Sociodemographic, symptom testing and exposure history by race/ethnicity
- 301 Compared to non-Hispanic white individuals, individuals identifying as Hispanic/Latino/Latina
- 302 were younger and had attained lower education levels (Table 4). They had higher rates of
- 303 unemployment at the start of the pandemic and were more likely to have their salary impacted by
- 304 COVID-19. They were more likely to work at a place that offered no benefits such as paid sick
- 305 leave or work-from-home and were more likely to use the bus as a means of transportation.
- 306 Housing conditions were also different, with Hispanic/Latino/Latina individuals more likely to
- 307 live in apartments or condominiums, rent instead of owning their homes, and report a higher
- 308 density of individuals living in the household.
- 309

310 **Discussion**

- 311 We estimated the citywide prevalence of SARS-CoV-2 IgG antibodies to be 13.1% in the City of
- 312 Holyoke at the end of a second surge of the pandemic in the Commonwealth of Massachusetts
- between November 2020 and January 2021, prior to widespread vaccination in this community.
- 314 We identified several groups at high risk of prior infection, on the basis of an elevated risk for
- 315 SARS-CoV-2 antibodies, which could be targeted for COVID-19-related public health
- 316 interventions.

- 318 In April 2020, a serosurvey using convenience sampling of asymptomatic individuals in the
- 319 predominantly Hispanic community of Chelsea, MA, demonstrated a seroprevalence of 31.5%.¹⁷
- 320 This serosurvey was limited by non-representative convenience sampling that likely resulted in a
- 321 biased estimate, and use of a rapid lateral flow immunoassay. Later, between July and August
- 322 2020, a university-related population and their household members in Massachusetts

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

demonstrated a lower seroprevalence of 4 - 5.3%.¹⁸ Our findings in this study conducted several months later are consistent with the increasing number of reported cases during the second surge of COVID-19 in MA. However, the seroprevalence measured in this study was not as high as would be expected approximately ten months into the pandemic. This may be in part due to the impact of decaying antibody titers, the kinetics of which vary depending on the population.¹⁹

329 Individuals identifying as Hispanic or Latino/Latina had a higher seroprevalence estimate 330 compared to those identifying as non-Hispanic white, suggesting that these members of the 331 community were at high risk of SARS-CoV-2 infection. Although confidence intervals around 332 effect estimates were wide, this finding is consistent with myriad prior studies documenting 333 racial and ethnic disparities in SARS-CoV-2 metrics affecting minoritized communities 334 nationally and in Massachusetts, including disparities in testing, infections, hospitalizations, and deaths.^{20,21} There are multiple potential mediators of these disparities, lending support to a true 335 336 difference in risk. In Holyoke, most Hispanic/Latino/Latina communities live in census tracts 337 characterized by high socioeconomic deprivation.¹⁵ In our study population, compared to non-338 Hispanic white individuals, individuals identifying as Hispanic/Latino/Latina reported lower 339 education levels, higher unemployment rates, have lower access to benefits such as paid sick 340 leave or work-from-home, and more likely to live in high-density housing. Larger seroprevalence 341 studies are needed to identify the key mediators of the relationship between race/ethnicity and 342 risk of SARS-CoV-2 infection, which can then inform public health interventions tailored to 343 these populations.

344

345 Interestingly, individuals from predominantly Spanish-speaking households, almost all who 346 identified as Hispanic/Latino/Latina, had a seroprevalence estimate higher than individuals from 347 English-speaking households. We are not aware of data regarding the availability of language 348 concordant public health messaging and outreach in this community; however, our experience 349 suggests this was limited in Massachusetts, especially during the early phases of the pandemic. 350 The absence of linguistically concordant public health interventions may directly impact an 351 individual's ability to understand and apply preventive guidance, and thus mediate SARS-CoV-2 352 infection risk.²² Larger and longitudinal serosurveys among populations at high risk are needed 353 to better quantify the magnitude of these relationships.

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

354

355 With regards to the relationship between seropositivity and SARS-CoV-2 exposure history, this 356 study corroborates recent findings. Seroprevalence was higher among individuals with a 357 COVID-19 exposure that was a household member compared to an exposure to a non-household 358 member. This finding highlights the greater importance of intra-household exposures compared to exposure to non-household members.²³ Given the role of intra-household transmission, public 359 360 health interventions and resources should be targeted to preventing transmission in the 361 household, such as providing isolation and quarantine sites outside the home, appropriate PPE 362 for individuals taking care of sick family members, timely and sequential testing for exposed 363 household members, and guidance on how to safely distance within the home. 364

365 Our findings also identify an important testing gap. Overall, the prevalence of any anti-SARS-

366 CoV-2 antibodies (measured by IgG or IgM) in this survey corresponds to a cumulative case

367 count of 5,593 compared to the city's actual case count of 3,963 on January 28th, 2021 based on

368 testing by RT-PCR.²⁴ By this estimate, nearly one third of all SARS-CoV-2 infections in

369 Holyoke were undetected by existing surveillance and screening mechanisms. This level of

370 underascertainment is lower than that demonstrated in other serosurveys throughout the US, a

371 finding that may be explained by the high availability of testing throughout the City of Holyoke,

372 where two public testing sites were established.^{25,26} However, this discrepancy highlights an

important testing gap that should be addressed as we prepare for subsequent outbreaks of SARS-

374 CoV-2, future pandemics and other diseases of public health importance.

375

376 Our findings also provide potential insight into community-level immunity. Our understanding 377 of immunity following SARS-CoV-2 infection is limited. We do not yet know what level of 378 protection antibodies against SARS-CoV-2 following natural infection provide against 379 subsequent infection or how emerging variants may impact this. It is likely that immunity is 380 more complex than simply the presence of antibodies and relies on other immune-mediating 381 mechanisms such as long-term memory B-cell and T-cell responses. However, the low 382 prevalence of antibodies in this population suggests that at the time of the study, many 383 individuals in the city were vulnerable to infection with SARS-CoV-2. This vulnerability can 384 now be immediately addressed by vaccination. Yet as of May 2021, vaccination rates in

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

Hampden County, MA where Holyoke is located were the lowest in the state.²⁷ Furthermore, as 385 386 of August 31th in Holyoke the percentage of fully vaccinated individuals identifying as 387 Hispanic/Latino/Latina, the group noted to have a high prevalence of SARS-CoV-2 antibodies, 388 was only 32.8%, compared to 59.3% of the non-Hispanic white population.²⁸ As such, an 389 emphasis on the rapid delivery of SARS-CoV-2 vaccines to this city is paramount, with a focus 390 on the most-impacted communities. As vaccination progresses, seroepidemiological surveys 391 conducted at the local level will continue to provide key insights by monitoring the prevalence of 392 antibodies as markers of vaccination and natural infection, identifying high-risk groups or areas 393 of low-seroprevalence where vaccination should be focused, and allowing for nuanced and local 394 public health efforts.

395

396 This study has several limitations. First, the small sample size led to estimates with wide 95% 397 credible intervals, precluding us from formally comparing seroprevalence between groups and 398 conducting multivariable analyses. Second, our analysis does not account for waning antibody 399 levels, which decay over time.¹¹ Third, because we did not interview individuals that declined to 400 participate or did not respond to survey invitation, it is possible that non-response bias may be 401 affecting our findings, though we proactively followed up with households that did not respond 402 to the study via telephone calls and home visits. Fourth, this study was conducted using a single 403 assay. Several studies have shown that variation in the sensitivity and specificity of the serologic test used in a serosurvey can affect seroprevalence estimates.²⁹ To limit the effect of this, we 404 405 used a test that had previously been validated in Massachusetts and conducted a sensitivity 406 analysis using other plausible test sensitivity and specificity values. Finally, we excluded nursing 407 homes and congregate living facilities from this study. Holyoke has a high density of such 408 facilities, and early on during the pandemic suffered a large outbreak at one of these.³⁰ However, 409 our goal was to assess community-level epidemiology, as community transmission seems to now 410 be the major driver of the pandemic.

411

412

413 **Conclusion**

In conclusion, in this SARS-CoV-2 serosurvey of Holyoke, Massachusetts, between November
2020 – January 2021, antibody prevalence was higher than prior serosurveys in the region, but

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

416 far from accepted thresholds of "herd immunity." Risk of infection was high among the

417 Hispanic/Latino/Latina community, the same community with the lowest SARS-CoV-2

418 vaccination rates in the county. A high prevalence of SARS-CoV-2 antibodies was also noted

419 among other subgroups such as Spanish-speakers and those with household exposures to

420 COVID-19. These differences in infection risk documented through the first year of the

421 pandemic will likely continue absent the necessary locally-focused public health response

- 422 efforts.
- 423

424 Though national serosurveys provide insights regarding the evolution of the COVID-19

425 pandemic overall, their scale often precludes an understanding of local details, which are key in

426 pandemic response given the diverse nature of outbreaks throughout the country and the need for

427 local response that matches local issues. City-level serosurveys can provide local authorities with

428 a clearer understanding of disparate viral transmission at a granular level and identify areas of

429 focus to optimize a community-tailored public health response. As we deploy public health

430 efforts to prevent COVID-19, local serosurveys should be implemented more widely. In

431 Holyoke, MA – and in other areas of the US – disparities in SARS-CoV-2 risk must be addressed

432 through proactive public health interventions.

433

434 Acknowledgments

We would like to thank other members of the Holyoke Board of Health for their logistical and
administrative support with this study. We would also like to thank Alex Morse and Mike
Bloomberg for their support and advocacy, Miriam Kwarteng-Siaw for contributing to the
implementation of the study and Joseph Rhatigan and the Brigham and Women's Hospital
Division of Global Health Equity for supporting WRM and CPN while in Holyoke. We would
like to acknowledge Aaron G. Schmit at the Ragon Institute of MGH, MIT and Harvard for
supplying the SARS-CoV-2 RBD protein and monoclonal antibodies.

442

443

444 Funding

445 This work was supported by the Sullivan Family Foundation (to L.C.I.), the Harvard Data

446 Science Institute Bias² program (S.M.S.) and funding from the US Centers for Disease Control

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

- 447 and Prevention (U01CK000490 to R.C.C. and J.B.H.). Funding sources played no role in study
- 448 design; in the collection, analysis, and interpretation of data; in the writing of the report; and in
- the decision to submit the paper for publication.
- 450
- 451

452 **Conflicts of Interest Statement**

- 453 None of the listed authors report conflicts of interests pertaining to this study.
- 454
- 455
- 456
- 457
- 458 **Figure and Table Legends**
- 459 **Figure 1. Study Participant Flow Diagram.**
- 460 Figure 2. Seroprevalence by Medical, Symptom, Testing and Exposure History. *n refers to
- the number of individuals that tested positive. N refers to the total number of individuals that
- 462 responded "Yes" the given question. ⁺Three individuals that didn't remember their test results
- 463 and four individuals that had not received their test results at the time of the survey.
- 464 **Table 1.** Unweighted demographic characteristics of survey participants compared with 2019
- 465 American Community Survey estimates for the city.
- 466 **Table 2.** Seroprevalence by antibody positivity profile.
- 467 **Table 3.** Seroprevalence by sociodemographic characteristics.
- 468 **Table 4.** Sociodemographic, symptom, testing and exposure history stratified by race/ethnicity.
- 469

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

470 **References**

- Wu SL, Mertens AN, Crider YS, et al. Substantial underestimation of SARS-CoV-2
 infection in the United States. *Nat Commun.* 2020;11(1):4507. doi:10.1038/s41467-020 18272-4
- 474 2. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections,
- 475 Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. *JAMA* 476 *Netw Open.* 2021;4(1):e2033706. doi:10.1001/jamanetworkopen.2020.33706
- 477 3. Chen X, Chen Z, Azman AS, et al. Serological evidence of human infection with SARS478 CoV-2: a systematic review and meta-analysis. *Lancet Glob Health*. 2021;0(0).
 479 doi:10.1016/S2214-109X(21)00026-7
- 480 4. Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites
 481 in the United States, March 23-May 12, 2020. *JAMA Intern Med.* 2020;180(12):1576.
 482 doi:10.1001/jamainternmed.2020.4130
- 483 5. Lemieux JE, Siddle KJ, Shaw BM, et al. Phylogenetic analysis of SARS-CoV-2 in Boston
 484 highlights the impact of superspreading events. *Science*. 2021;371(6529).
 485 doi:10.1126/science.abe3261
- 486 6. Holyoke, MA & Massachusetts | Data USA. Data USA (2018). Holyoke, MA &
 487 Massachusetts. Accessed June 4, 2021. https://datausa.io/profile/geo/holyoke488 ma/?compare=massachusetts
- 489
 489
 490
 490
 491
 491
 491
 491
 491
 492
 493
 494
 494
 494
 495
 495
 496
 496
 497
 497
 498
 498
 498
 499
 499
 490
 490
 490
 490
 490
 490
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
- 492 8. Coronavirus Hot Spots: The 50 Mass. Communities With the Highest Rates of Cases. NBC
 493 Boston. Accessed June 8, 2021. https://www.nbcboston.com/news/coronavirus/coronavirus494 hot-spots-the-50-mass-communities-with-the-highest-rates-of-cases/2123761/
- 495
 9. Iyer AS, Azman AS, Bouhenia M, et al. Dried Blood Spots for Measuring Vibrio cholerae496 specific Immune Responses. *PLoS Negl Trop Dis*. 2018;12(1):e0006196.
 497 doi:10.1371/journal.pntd.0006196
- 498 10. Valentine-Graves M, Hall E, Guest JL, et al. At-home self-collection of saliva,
 499 oropharyngeal swabs and dried blood spots for SARS-CoV-2 diagnosis and serology: Post500 collection acceptability of specimen collection process and patient confidence in specimens.
 501 *PloS One*. 2020;15(8):e0236775. doi:10.1371/journal.pone.0236775
- 11. Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses
 to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. *Sci Immunol.* 2020;5(52). doi:10.1126/sciimmunol.abe0367

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

- 505 12. Wiens KE, Mawien PN, Rumunu J, et al. Seroprevalence of Severe Acute Respiratory
- Syndrome Coronavirus 2 IgG in Juba, South Sudan, 2020. *Emerg Infect Dis*. 2021;27(6).
 doi:10.3201/eid2706.210568
- 508 13. Slater DM. Preparation of Elutions from Dried Blood Spots for ELISAs. protocols.io.
 509 doi:10.17504/protocols.io.bsrnnd5e
- 510 14. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG
 511 antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *The Lancet*.
 512 2020;396(10247):313-319. doi:10.1016/S0140-6736(20)31304-0
- 513 15. Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease
 514 Registry/Geospatial Research, Analysis, and Services Program. CDC/ATSDR Social
 515 Vulnerability Index 2018 Database, Massachusetts.
- 516 https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html.
 517 Accessed on 6/18/2021.
- 518 16. Lumley T. Survey: Analysis of Complex Survey Samples.; 2020. Accessed May 6, 2021.
 519 https://CRAN.R-project.org/package=survey
- 520 17. Naranbhai V, Chang CC, Beltran WFG, et al. High Seroprevalence of Anti-SARS-CoV-2
 521 Antibodies in Chelsea, Massachusetts. *J Infect Dis.* 2020;222(12):1955-1959.
 522 doi:10.1093/infdis/jiaa579
- 523 18. Snyder T, Ravenhurst J, Cramer EY, et al. Serological surveys to estimate cumulative
 524 incidence of SARS-CoV-2 infection in adults (Sero-MAss study), Massachusetts, July–
 525 August 2020: a mail-based cross-sectional study. *BMJ Open*. 2021;11(8):e051157.
 526 doi:10.1136/bmjopen-2021-051157
- 527 19. Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in humans: A
 528 systematic review. *PloS One*. 2020;15(12):e0244126. doi:10.1371/journal.pone.0244126
- 529 20. Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Lockman S, Ojikutu BO. Disparities
 530 in SARS-CoV-2 Testing in Massachusetts During the COVID-19 Pandemic. *JAMA Netw* 531 *Open*. 2021;4(2):e2037067. doi:10.1001/jamanetworkopen.2020.37067
- 532 21. Mackey K, Ayers CK, Kondo KK, et al. Racial and Ethnic Disparities in COVID-19–Related
 533 Infections, Hospitalizations, and Deaths. *Ann Intern Med.* 2020;174(3):362-373.
 534 doi:10.7326/M20-6306
- 535 22. Maleki P, Al Mudaris M, Oo KK, Dawson-Hahn E. Training Contact Tracers for Populations
 536 With Limited English Proficiency During the COVID-19 Pandemic. *Am J Public Health*.
 537 2021;111(1):20-24. doi:10.2105/AJPH.2020.306029
- 538 23. Yu H-J, Hu Y-F, Liu X-X, et al. Household infection: The predominant risk factor for close
 539 contacts of patients with COVID-19. *Travel Med Infect Dis*. 2020;36:101809.
 540 doi:10.1016/j.tmaid.2020.101809

Matias and Fulcher et al. SARS-CoV-2 Antibodies in Holyoke, MA

- 541 24. Archive of COVID-19 Weekly Public Health Reports | Mass.gov. Accessed May 7, 2021.
 542 https://www.mass.gov/info-details/archive-of-covid-19-weekly-public-health-reports
- 543 25. Menachemi N, Yiannoutsos CT, Dixon BE, et al. Population Point Prevalence of SARS544 CoV-2 Infection Based on a Statewide Random Sample Indiana, April 25-29, 2020.
 545 *MMWR Morb Mortal Wkly Rep.* 2020;69(29):960-964. doi:10.15585/mmwr.mm6929e1
- 546 26. Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large
 547 nationwide sample of patients on dialysis in the USA: a cross-sectional study. *Lancet Lond*548 *Engl.* 2020;396(10259):1335-1344. doi:10.1016/S0140-6736(20)32009-2
- 549 27. Weisman R. In state's least immunized county, vaccine holdouts remain as wariness persists
 550 The Boston Globe. *Boston Globe*. https://www.bostonglobe.com/2021/05/22/metro/states551 least-immunized-county-vaccine-holdouts-remain-wariness-persists/. Published May 22,
 552 2021. Accessed June 18, 2021.
- 28. COVID-19 Vaccine Tracker. Pioneer Institute. Published April 16, 2021. Accessed
 September 11, 2021. https://pioneerinstitute.org/covid/covid-19-vaccine-tracker/
- 555 29. Fotis C, Meimetis N, Tsolakos N, et al. Accurate SARS-CoV-2 seroprevalence surveys
 556 require robust multi-antigen assays. *Sci Rep.* 2021;11(1):6614. doi:10.1038/s41598-021557 86035-2
- 30. The COVID-19 Outbreak at the Soldiers' Home in Holyoke. An Independent Investigation
 Conducted for the Governor of Massachusetts.; 2020:174.
- 560

Matias and Fulcher et al. SARS-CoV-2 Antibody Seroprevalence in Holyoke, MA

		Responded to		Provided	dy		
		Survey		Sample		Holyoke City ¹	
Characteristic		N = 472	%	N = 328	%	N = 40241	%
Age group (years)	Median (IQR) [*]						
0-19	14 (8,16)	50	10.6	27	8.2	10406	25.8
20 - 44	33 (27, 37.25)	130	27.5	76	23.2	14335	35.7
45 – 59	53 (50.25 <i>,</i> 56)	135	28.6	94	28.7	7607	18.9
60 - 84	68 (64, 73)	149	31.6	123	37.5	7019	17.4
85 and over	88 (86.5, 89.25)	8	1.7	8	2.4	874	2.2
Gender							
Female		263	55.7	180	54.9	20747	51.6
Male		200	42.4	139	42.4	19494	48.4
Transgender woma	in	1	0.2	1	0.3	_+	
Transgender man		0	0.0	0	0	-	
Non-binary		7	1.5	7	2.1	-	
Prefer not to answe	er	1	0.2	1	0.3	-	
Other		0	0.0	0	0	-	
Race/Ethnicity							
Hispanic or Latino/	Latina	126	26.7	66	20.1	21704	53.9
Non-Hispanic or No	on-Latino/Latina	346	73.3	262	79.9	18537	46.3
White		311	65.9	239	72.9	16636	41.3
Black or Africar	n American	10	2.1	5	1.5	1162	2.9
Asian		7	1.5	5	1.5	239	0.0
AIAN ²		1	0.2	1	0.3	78	0.2
NHPI ³		0	0.0	0	0.0	0	0.0
Other Race		6	1.3	5	1.5	3	0.0
Two or more ra	ices	6	1.3	2	0.6	419	1.0
Prefer not to answe	er	5	1.1	5	1.5	-	

Table 1. Unweighted demographic characteristics of survey participants compared with 2019 American Community Survey estimates for the city

¹U.S. Census Bureau (2019). American Community Survey, Demographic and Housing Estimates. Table DP05. ²AIAN = American Indian or Alaskan Native.

³NHPI = Native Hawaiian and Other Pacific Islander.

*Median (IQR) for the population of 328 individuals providing an antibody sample.

+- indicates that this data was not available in the American Community Survey.

Matias and Fulcher et al. SARS-CoV-2 Antibody Seroprevalence in Holyoke, MA

Characteristic	No. tested	No. Positive	Seroprevalence % (95% Cl)
IgG	328	25	13.1 (6.9-22.3)
IgG only	328	18	7.8 (3.4-16.4)
lgM	328	9	11.0 (2.3-25.9)
IgM only	328	2	0 (0-5.0)
lgG or lgM	328	27	13.6 (6.7-23.7)

Table 2. Seroprevalence by antibody positivity profile

Matias and Fulcher et al. SARS-CoV-2 Antibody Seroprevalence in Holyoke, MA

				Weighted ⁴ Seroprevalence
	Characteristic (N if not 328)	N	n	% (95% CI)
Age group	s (years)			
	0-19	27	2	11.2 (1.9-32.9)
	20-44	76	10	17.6 (7.5-32.4)
	45-59	94	6	9.8 (3.4-21.1)
	60 and above	131	7	8.9 (3.6-17.4)
Gender				
	Female	180	15	14.4 (6.7-26.0)
	Grouped categories (Male or Non-binary)	148	10	11.6 (5.0-22.4)
Race/Ethn	icity			
	non-Hispanic, White	239	16	9.4 (4.6-16.4)
	Hispanic or Latino/Latina	66	8	16.1 (6.2-31.8)
	non-Hispanic, Grouped categories	23	1	7.3 (0.7-24.4)
Social Vul	nerability Index			-
	High	185	16	14.4 (7.1-25.5)
	Low	143	9	8.2 (3.1-16.9)
Primary la	nguage spoken in the household			
	English	275	18	10.2 (5.2-18.0)
	Spanish	36	7	21.9 (8.3-43.9)
	Multi-lingual/Other	16	0	3.9 (0.1-27.0)
	Missing	1	0	
Highest ec	lucation level (N = 305) [*]			
	Some high school or less	22	2	12.5 (2.2-34.8)
	High school/GED or some college	95	8	15.2 (5.9-29.0)
	Associate or bachelor's degree	101	7	12.6 (4.8-24.7)
	Master's doctorate or professional degree	80	6	11.7 (4.0-23.6)
	Missing	7	0	
Employme	ent status on February 1st, 2020 (N = 305) [*]			
	Working	181	19	18.1 (9.7-29.6)
	Not Working	94	2	3.9 (0.5-12.7)
	Other	29	2	11.5 (1.1-32.0)
	Missing	1	0	. ,
Worked o	utside home during "stay at home" order (N=305)*			
	No	211	13	10.8 (4.8-20.1)
	Yes	93	10	19.5 (9.4-33.8)
	Missing	1	0	· · · ·
Worked as	s a health worker in a healthcare setting (N=93) ^{*+}		-	
	No	75	7	13.1 (4.4-27.7)

Table 3. Seroprevalence¹ by sociodemographic characteristics

Matias and Fulcher et al. SARS-CoV-2 Antibody Seroprevalence in Holyoke, MA

Yes	18	3	20.7 (4.8-53.4)
Workplace offered paid sick leave, work-from-home,			
overtime, or hazard pay during Mar – June (N=93) ^{*+}			
None of the above	31	4	15.3 (3.2-38.7)
1 – 2 of the above	56	5	13.6 (4.5-30.9)
3 – 4 of the above	6	1	8.4 (0.3-45.1)
Travel since February 1st, 2020 (N = 328)			
No	114	8	12.5 (4.5-25.2)
Yes, to a different city	117	5	6.9 (1.4-16.2)
Yes, to a different state	88	8	10.8 (3.4-26.5)
Yes, to a different country	7	4	55.5 (14.2-98.0)
Missing	2	0	
Annual household income (N = 328)			
Less than \$15,000	21	6	33.8 (10.6-66.9)
\$15,000 - \$50,000	69	1	2.0 (0-14.7)
\$50,000 - \$80,000	64	3	7.4 (0.3-22.4)
\$80,000 - \$160,000	94	9	15.8 (6.3-29.2)
>\$160,000	24	4	13.9 (2.7-38.3)
Prefer not to answer	53	2	8.2 (0.1-26.0)
Missing	3	0	
Home type (N = 328)			
Single Family	189	11	8.4 (3.6-16.1)
Multi-family	67	5	14.0 (4.2-29.4)
Apartment or condominium	67	8	15.9 (5.8-33.4)
Other	3	1	23.1 (2.2-69.8)
Missing	2	0	
Rent or own the home (N = 328)			
Someone in the household owns the home	235	16	12.1 (5.6-21.5)
We have a landlord	88	8	13.8 (5.0-29.4)
Missing	5	1	
Number of people living in the household			
One	65	2	4.7 (0.3-14.7)
Two	130	11	13.9 (6.1-26.0)
Three	73	3	3.0 (0.0-17.1)
Four or more	60	9	25.8 (9.2-50.6)

¹Seroprevalence for demographics groups based on IgG antibody positivity (i.e., at least IgG positive). ²N refers to the total numbers of individuals in each category.

³n refers to the total number of individuals seropositive for IgG in each group.

⁴Weights were computed as the inverse probability of selection and adjusted so that the marginal distribution of age group, gender, race/ethnicity, and social vulnerability index of the sample agreed with population estimates. ^{*}Among adult respondents only.

*Among individuals that responded "Yes" to working outside the home during the "stay at home" order.

Matias and Fulcher et al. SARS-CoV-2 Antibody Seroprevalence in Holyoke, MA

Table 4. Sociodemographic, symptom, testing and exposure history stratified by race/ethnicity.

	Hispanic,	Hispanic, White,		
	Latino/Latina	non-Hispanic	race/ethnicity, non-Hispanic	
Characteristic (N if not 328 ¹)	66	239	23	
Age group (years) (%)				
0-19	12 (18.2)	14 (5.9)	1(4.3)	
20-44	14 (21.2)	54 (22.6)	8 (34.8)	
45-59	24 (36.4)	64 (26.8)	6 (26.1)	
60-84	15 (22.7)	100 (41.8)	8 (34.8)	
85+	1(1.5)	7 (2.9)	0 (0.0)	
Age (years) (median [IQR])	53.00	57.00	50.00	
	[31.50, 59.00]	[39.00, 68.00]	[35.50, 62.00]	
Gender (%)				
Female	27 (40.9)	102 (42.7)	10 (43.5)	
Male	39 (59.1)	130 (54.4)	11 (47.8)	
Trans woman	0 (0.0)	1(0.4)	0 (0.0)	
Non-binary	0 (0.0)	5 (2.1)	2 (8.7)	
Prefer not to answer	0 (0.0)	1(0.4)	0 (0.0)	
Primary language spoken in the household (%) (N = 327)				
English	20 (30.3)	234 (98.3)	21 (91.3)	
Spanish	35 (53.0)	1 (0.4)	0 (0.0)	
Multi-lingual	10 (15.2)	2 (0.8)	. ,	
Other	1 (1.5)	1(0.4)	1 (4.3)	
Highest education level (%) (N=298)*				
Some high school or less	16 (32.7)	5 (2.2)	1(4.8)	
High school/GED or some college	18 (36.7)	74 (32.5)	3 (14.3)	
Associate or bachelor's degree	13 (26.5)	78 (34.2)	10 (47.6)	
Master's doctorate or professional degree	2 (4.1)	71 (31.1)	7 (33.3)	
Employment status on February 1st, 2020 (%) (N=304)*		. ,		
Not Working	17 (31.5)	73 (32.0)	4 (18.2)	
Working	22 (40.7)	142 (62.3)	· · ·	
Other	15 (27.8)	13 (5.7)	. ,	
Salary impacted by COVID-19 (%) (N=304)*			- (
No	31 (57.4)	165 (72.4)	14 (63.6)	
Yes	23 (42.6)	63 (27.6)	8 (36.4)	
Worked outside home during "stay at home" order (%) (N=304)*	23 (42.0)	03 (27.0)	0 (30.4)	
No	40 (74.1)	154 (67.5)	17 (77.3)	

Matias and Fulcher et al. SARS-CoV-2 Antibody Seroprevalence in Holyoke, MA

Yes	11 (25 0)	74 (32.5)	5 (22.7)
Worked as a health worker in a healthcare setting (%)	14 (23.3)	74 (52.5)	5(22.7)
(N=93)**			
No	12 (85.7)	59 (79.7)	4 (80.0)
Yes	2 (14.3)	15 (20.3)	1 (20.0)
Workplace offered paid sick leave, work-from-home,			
overtime, or hazard pay during Mar – June (%)			
(N=93)**	4 (28 6)	40 (66 2)	3 (60.0)
1 or 2	4 (28.6)	. ,	. ,
3 or 4	. ,	5 (6.8)	0(0.0)
None	9 (64.3)	20 (27.0)	2 (40.0)
Could you afford to stay home sick from work? (%) (N=92)**			
No	6 (42.9)	7 (9.6)	2 (40.0)
Yes	8 (57.1)	66 (90.4)	3 (60.0)
Have you had any symptoms since Feb, 2020? (%) ***			
No	26 (39.4)	116 (48.5)	13 (56.5)
Yes	40 (60.6)	123 (51.5)	10 (43.5)
COVID-19 testing history (%) (N=326)			
I have always tested negative	25 (38.5)	107 (44.8)	9 (40.9)
I have never been tested for COVID-19	35 (53.8)	120 (50.2)	12 (54.5)
I tested positive at least once	5 (7.7)	12 (5.0)	1(4.5)
Exposure to individual with COVID-19? (%) (N=327)			
I have no known exposure to COVID-19	50 (75.8)	186 (78.2)	20 (87.0)
I was exposed to a household member with COVID-19	6 (9.1)	10 (4.2)	0 (0.0)
I was exposed to a non-household member with COVID-19	10 (15.2)	42 (17.6)	3 (13.0)
Exposed to individual with respiratory illness? (%) (N=326)			
Household member	5 (7.6)	6(2.5)	0(0.0)
No known exposure	58 (87.9)	204 (86.1)	20 (87.0)
Non-household member	3 (4.5)	27 (11.4)	3 (13.0)
Have you ever been contacted by a contact tracer? (%) (N=327)			
No	66 (100.0)	228 (95.8)	23 (100.0)
Yes	0 (0.0)	10 (4.2)	0 (0.0)
Did you use the bus since Feb 2020? (%) (N=323)			
No	62 (93.9)	230 (97.9)	22 (100.0)
Yes	4 (6.1)	5 (2.1)	0 (0.0)
Travel since February 1st, 2020 (%) (N=326)			

Matias and Fulcher et al. SARS-CoV-2 Antibody Seroprevalence in Holyoke, MA

Different city 8 (12.1) 99 (41.6) 10 (45.5) Different country 4 (6.1) 3 (1.3) 0 (0.0) Different state 14 (21.2) 71 (29.8) 3 (13.6) No 40 (60.6) 65 (27.3) 9 (40.9) Home type (%) (N=326) 12 (18.2) 165 (69.6) 12 (52.2) Multi-family 18 (27.3) 42 (17.7) 7 (30.4) Apartment or condominium 35 (53.0) 28 (11.8) 4 (17.4) Other 1 (1.5) 2 (0.8) 0 (0.0) Rent or own the home (%) (N=323) 33 (50.0) 189 (80.4) 13 (59.1) We have a landlord 33 (50.0) 189 (80.4) 13 (59.1) Number of household members (mean (SD)) 3.30 (2.31) 2.37 (1.07) 2.22 (0.80) Annual household income (%) (N=325) U U 14 (4.1) Less than \$15,000 15 (22.7) 5 (2.1) 1 (4.3) \$15,000 - \$50,000 8 (12.1) 50 (21.2) 6 (26.1) \$26 (30.0) 9 (40.9) 0 (0.0) 23 (9.7) 1 (4.3) <t< th=""><th></th><th></th><th></th><th></th></t<>				
Different state 14 (21.2) 71 (29.8) 3 (13.6) No 40 (60.6) 65 (27.3) 9 (40.9) Home type (%) (N=326)	Different city	8 (12.1)	99 (41.6)	10 (45.5)
No 40 (60.6) 65 (27.3) 9 (40.9) Home type (%) (N=326)	Different country	4 (6.1)	3 (1.3)	0 (0.0)
Home type (%) (N=326) Image: Single Family 12 (18.2) 165 (69.6) 12 (52.2) Multi-family 18 (27.3) 42 (17.7) 7 (30.4) Apartment or condominium 35 (53.0) 28 (11.8) 4 (17.4) Other 1 (1.5) 2 (0.8) 0 (0.0) Rent or own the home (%) (N=323) Someone in the household owns house 33 (50.0) 189 (80.4) 13 (59.1) We have a landlord 33 (50.0) 46 (19.6) 9 (40.9) Number of household members (mean (SD)) 3.30 (2.31) 2.37 (1.07) 2.22 (0.80) Annual household income (%) (N=325) Less than \$15,000 15 (22.7) 5 (2.1) 1 (4.3) \$15,000 - \$50,000 19 (28.8) 44 (18.6) 6 (26.1) \$80,000 - \$160,000 4 (6.1) 84 (35.6) 6 (26.1) \$80,000 - \$160,000 4 (6.1) 84 (35.6) 6 (26.1) \$80,000 - \$160,000 9 (0.00) 23 (9.7) 1 (4.3) Prefer not to answer 20 (30.3) 30 (12.7) 3 (13.0) Do you have a computer with internet at home? (%) (M=322) 37 (60.7) </td <td>Different state</td> <td>14 (21.2)</td> <td>71 (29.8)</td> <td>3 (13.6)</td>	Different state	14 (21.2)	71 (29.8)	3 (13.6)
Single Family 12 (18.2) 165 (69.6) 12 (52.2) Multi-family 18 (27.3) 42 (17.7) 7 (30.4) Apartment or condominium 35 (53.0) 28 (11.8) 4 (17.4) Other 1 (1.5) 2 (0.8) 0 (0.0) Rent or own the home (%) (N=323) 33 (50.0) 189 (80.4) 13 (59.1) We have a landlord 33 (50.0) 46 (19.6) 9 (40.9) Number of household members (mean (SD)) 3.30 (2.31) 2.37 (1.07) 2.22 (0.80) Annual household income (%) (N=325) - - - - Less than \$15,000 15 (22.7) 5 (2.1) 1 (4.3) -	No	40 (60.6)	65 (27.3)	9 (40.9)
Multi-family 18 (27.3) 42 (17.7) 7 (30.4) Apartment or condominium 35 (53.0) 28 (11.8) 4 (17.4) Other 1 (1.5) 2 (0.8) 0 (0.0) Rent or own the home (%) (N=323) 33 (50.0) 189 (80.4) 13 (59.1) We have a landlord 33 (50.0) 189 (80.4) 13 (59.1) We have a landlord 33 (50.0) 46 (19.6) 9 (40.9) Number of household members (mean (SD)) 3.30 (2.31) 2.37 (1.07) 2.22 (0.80) Annual household income (%) (N=325)	Home type (%) (N=326)			
Apartment or condominium Other 35 (53.0) 28 (11.8) 4 (17.4) Other 1 (1.5) 2 (0.8) 0 (0.0) Rent or own the home (%) (N=323) 3 5 33 (50.0) 189 (80.4) 13 (59.1) We have a landlord 33 (50.0) 46 (19.6) 9 (40.9) 3.30 (2.31) 2.37 (1.07) 2.22 (0.80) Annual household income (%) (N=325) 1 1 (1.3) 5 (2.1) 1 (1.4.3) \$15,000 - \$50,000 15 (22.7) 5 (2.1) 1 (4.3) \$15,000 - \$50,000 19 (28.8) 44 (18.6) 6 (26.1) \$50,000 - \$80,000 8 (12.1) 50 (21.2) 6 (26.1) \$80,000 - \$160,000 4 (6.1) 84 (35.6) 6 (26.1) \$\$160,000 0 (0.0) 23 (9.7) 1 (4.3) Prefer not to answer 20 (30.3) 30 (12.7) 3 (13.0) Do you have a computer with internet at home? (%) (N=322) No 23 (100.0) No 24 (39.3) 10 (4.2) 0 (0.0) 23 (100.0) Yes 37 (60.7) 228 (95.8) 23 (100.0)	Single Family	12 (18.2)	165 (69.6)	12 (52.2)
Other 1 (1.5) 2 (0.8) 0 (0.0) Rent or own the home (%) (N=323) 33 (50.0) 189 (80.4) 13 (59.1) We have a landlord 33 (50.0) 46 (19.6) 9 (40.9) Number of household members (mean (SD)) 3.30 (2.31) 2.37 (1.07) 2.22 (0.80) Annual household income (%) (N=325) Image: Comparison of the second secon	Multi-family	18 (27.3)	42 (17.7)	7 (30.4)
Rent or own the home (%) (N=323) 33 (50.0) 189 (80.4) 13 (59.1) We have a landlord 33 (50.0) 46 (19.6) 9 (40.9) Number of household members (mean (SD)) 3.30 (2.31) 2.37 (1.07) 2.22 (0.80) Annual household income (%) (N=325) Less than \$15,000 15 (22.7) 5 (2.1) 1 (4.3) \$15,000 - \$50,000 19 (28.8) 44 (18.6) 6 (26.1) \$50,000 - \$80,000 8 (12.1) 50 (21.2) 6 (26.1) \$80,000 - \$160,000 4 (6.1) 84 (35.6) 6 (26.1) >\$160,000 0 (0.0) 23 (9.7) 1 (4.3) Prefer not to answer 20 (30.3) 30 (12.7) 3 (13.0) Do you have a computer with internet at home? (%) (N=322) No 24 (39.3) 10 (4.2) 0 (0.0) Yes 37 (60.7) 228 (95.8) 23 (100.0) In the past 6 months, has your HH received any public assistance? (%) (N=3223)**** 1 (1.5) 47 (20.0) 7 (30.4) 1 type of assistance <td>Apartment or condominium</td> <td>35 (53.0)</td> <td>28 (11.8)</td> <td>4 (17.4)</td>	Apartment or condominium	35 (53.0)	28 (11.8)	4 (17.4)
Someone in the household owns house 33 (50.0) 189 (80.4) 13 (59.1) We have a landlord 33 (50.0) 46 (19.6) 9 (40.9) Number of household members (mean (SD)) 3.30 (2.31) 2.37 (1.07) 2.22 (0.80) Annual household income (%) (N=325) 15 (22.7) 5 (2.1) 1 (4.3) \$15,000 \$50,000 19 (28.8) 44 (18.6) 6 (26.1) \$50,000 \$80,000 8 (12.1) 50 (21.2) 6 (26.1) \$80,000 \$160,000 4 (6.1) 84 (35.6) 6 (26.1) \$\$160,000 0 (0.0) 23 (9.7) 1 (4.3) Prefer not to answer 20 (30.3) 30 (12.7) 3 (13.0) Do you have a computer with internet at home? (%) X X X (N=322) No 24 (39.3) 10 (4.2) 0 (0.0) Yes 37 (60.7) 228 (95.8) 23 (100.0) In the past 6 months, has your HH received any public assistance? (%) (N=3223)**** 1 (1.5) 47 (20.0) 7 (30.4) 1 type of assistance 12 (18.5) 89 (37.9) 6 (26.1)	Other	1(1.5)	2 (0.8)	0 (0.0)
We have a landlord 33 (50.0) 46 (19.6) 9 (40.9) Number of household members (mean (SD)) 3.30 (2.31) 2.37 (1.07) 2.22 (0.80) Annual household income (%) (N=325) 15 (22.7) 5 (2.1) 1 (4.3) \$15,000 - \$50,000 19 (28.8) 44 (18.6) 6 (26.1) \$50,000 - \$80,000 8 (12.1) 50 (21.2) 6 (26.1) \$80,000 - \$160,000 4 (6.1) 84 (35.6) 6 (26.1) \$\$160,000 0 (0.0) 23 (9.7) 1 (4.3) Prefer not to answer 20 (30.3) 30 (12.7) 3 (13.0) Do you have a computer with internet at home? (%) 24 (39.3) 10 (4.2) 0 (0.0) Yes 37 (60.7) 228 (95.8) 23 (100.0) In the past 6 months, has your HH received any public assistance? (%) (N=3223)**** 1 (1.5) 47 (20.0) 7 (30.4) No assistance 1 (1.5) 89 (37.9) 6 (26.1) 2 - 3 types of assistance 39 (60.0) 91 (38.7) 10 (43.5) 4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)	Rent or own the home (%) (N=323)			
Number of household members (mean (SD)) Annual household income (%) (N=325) 3.30 (2.31) 2.37 (1.07) 2.22 (0.80) Less than \$15,000 15 (22.7) 5 (2.1) 1 (4.3) \$15,000 - \$50,000 19 (28.8) 44 (18.6) 6 (26.1) \$50,000 - \$80,000 8 (12.1) 50 (21.2) 6 (26.1) \$80,000 - \$160,000 4 (6.1) 84 (35.6) 6 (26.1) \$\$160,000 0 (0.0) 23 (9.7) 1 (4.3) Prefer not to answer 20 (30.3) 30 (12.7) 3 (13.0) Do you have a computer with internet at home? (%) (N=322) No 24 (39.3) 10 (4.2) 0 (0.0) Yes 37 (60.7) 228 (95.8) 23 (100.0) 1 1 (1.5) 47 (20.0) 7 (30.4) 1 type of assistance 1 (1.5) 47 (20.0) 7 (30.4) 1 (43.5) 2 - 3 types of assistance 39 (60.0) 91 (38.7) 10 (43.5) 4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)	Someone in the household owns house	33 (50.0)	189 (80.4)	13 (59.1)
Annual household income (%) (N=325)Less than \$15,000 $15 (22.7)$ $5 (2.1)$ $1 (4.3)$ \$15,000 - \$50,000 $19 (28.8)$ $44 (18.6)$ $6 (26.1)$ \$50,000 - \$80,000 $8 (12.1)$ $50 (21.2)$ $6 (26.1)$ \$80,000 - \$160,000 $4 (6.1)$ $84 (35.6)$ $6 (26.1)$ >\$160,000 $0 (0.0)$ $23 (9.7)$ $1 (4.3)$ Prefer not to answer $20 (30.3)$ $30 (12.7)$ $3 (13.0)$ Do you have a computer with internet at home? (%) $(N=322)$ No $24 (39.3)$ $10 (4.2)$ $0 (0.0)$ Yes $37 (60.7)$ $228 (95.8)$ $23 (100.0)$ $1 (1.5)$ $47 (20.0)$ $7 (30.4)$ I type of assistance $12 (18.5)$ $89 (37.9)$ $6 (26.1)$ $2 - 3$ types of assistance $39 (60.0)$ $91 (38.7)$ $10 (43.5)$ $4 - 5$ types of assistance $13 (20.0)$ $8 (3.4)$ $0 (0.0)$	We have a landlord	33 (50.0)	46 (19.6)	9 (40.9)
Less than \$15,000 15 (22.7) 5 (2.1) 1 (4.3) \$15,000 - \$50,000 19 (28.8) 44 (18.6) 6 (26.1) \$50,000 - \$80,000 8 (12.1) 50 (21.2) 6 (26.1) \$80,000 - \$160,000 4 (6.1) 84 (35.6) 6 (26.1) >\$160,000 0 (0.0) 23 (9.7) 1 (4.3) Prefer not to answer 20 (30.3) 30 (12.7) 3 (13.0) Do you have a computer with internet at home? (%) (N=322) 37 (60.7) 228 (95.8) 23 (100.0) In the past 6 months, has your HH received any public assistance? (%) (N=3223)**** 1 (1.5) 47 (20.0) 7 (30.4) 1 type of assistance 12 (18.5) 89 (37.9) 6 (26.1) 2 - 3 types of assistance 39 (60.0) 91 (38.7) 10 (43.5) 4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)	Number of household members (mean (SD))	3.30 (2.31)	2.37 (1.07)	2.22 (0.80)
\$15,000 - \$50,000 19 (28.8) 44 (18.6) 6 (26.1) \$50,000 - \$80,000 8 (12.1) 50 (21.2) 6 (26.1) \$80,000 - \$160,000 4 (6.1) 84 (35.6) 6 (26.1) >\$160,000 0 (0.0) 23 (9.7) 1 (4.3) Prefer not to answer 20 (30.3) 30 (12.7) 3 (13.0) Do you have a computer with internet at home? (%) (N=322) 24 (39.3) 10 (4.2) 0 (0.0) Yes 37 (60.7) 228 (95.8) 23 (100.0) In the past 6 months, has your HH received any public assistance? (%) (N=3223)**** 1 (1.5) 47 (20.0) 7 (30.4) No assistance 1 (1.5) 89 (37.9) 6 (26.1) 2 - 3 types of assistance 39 (60.0) 91 (38.7) 10 (43.5) 4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)	Annual household income (%) (N=325)			
\$50,000 - \$80,000 8 (12.1) 50 (21.2) 6 (26.1) \$80,000 - \$160,000 4 (6.1) 84 (35.6) 6 (26.1) >\$160,000 0 (0.0) 23 (9.7) 1 (4.3) Prefer not to answer 20 (30.3) 30 (12.7) 3 (13.0) Do you have a computer with internet at home? (%) (N=322) 0 (0.0) 224 (39.3) 10 (4.2) 0 (0.0) Yes 37 (60.7) 228 (95.8) 23 (100.0) 37 (60.7) 228 (95.8) 23 (100.0) In the past 6 months, has your HH received any public assistance? (%) (N=3223)**** 1 (1.5) 47 (20.0) 7 (30.4) No assistance 1 (1.5) 89 (37.9) 6 (26.1) 2.6 (20.1) 2 - 3 types of assistance 39 (60.0) 91 (38.7) 10 (43.5) 4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)	Less than \$15,000	15 (22.7)	5 (2.1)	1(4.3)
\$80,000 - \$160,000 4 (6.1) 84 (35.6) 6 (26.1) >\$160,000 0 (0.0) 23 (9.7) 1 (4.3) Prefer not to answer 20 (30.3) 30 (12.7) 3 (13.0) Do you have a computer with internet at home? (%) 24 (39.3) 10 (4.2) 0 (0.0) (N=322) No 24 (39.3) 10 (4.2) 0 (0.0) Yes 37 (60.7) 228 (95.8) 23 (100.0) In the past 6 months, has your HH received any public assistance? (%) (N=3223)**** 1 (1.5) 47 (20.0) 7 (30.4) No assistance 1 (1.5) 89 (37.9) 6 (26.1) 2 - 3 types of assistance 39 (60.0) 91 (38.7) 10 (43.5) 4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)	\$15,000 - \$50,000	19 (28.8)	44 (18.6)	6 (26.1)
>\$160,000 0 (0.0) 23 (9.7) 1 (4.3) Prefer not to answer 20 (30.3) 30 (12.7) 3 (13.0) Do you have a computer with internet at home? (%) (N=322) Vertice	\$50,000 - \$80,000	8 (12.1)	50 (21.2)	6 (26.1)
Prefer not to answer 20 (30.3) 30 (12.7) 3 (13.0) Do you have a computer with internet at home? (%) 24 (39.3) 10 (4.2) 0 (0.0) (N=322) No 24 (39.3) 10 (4.2) 0 (0.0) Yes 37 (60.7) 228 (95.8) 23 (100.0) In the past 6 months, has your HH received any public assistance? (%) (N=3223)**** 1 (1.5) 47 (20.0) 7 (30.4) No assistance 1 (1.5) 89 (37.9) 6 (26.1) 2 (18.5) 89 (37.9) 6 (26.1) 2 - 3 types of assistance 39 (60.0) 91 (38.7) 10 (43.5) 4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)	\$80,000 - \$160,000	4 (6.1)	84 (35.6)	6 (26.1)
Do you have a computer with internet at home? (%) Image: Computer with internet at home? (%) No 24 (39.3) 10 (4.2) 0 (0.0) Yes 37 (60.7) 228 (95.8) 23 (100.0) In the past 6 months, has your HH received any public assistance? (%) (N=3223)**** 1 (1.5) 47 (20.0) 7 (30.4) No assistance 12 (18.5) 89 (37.9) 6 (26.1) 2 - 3 types of assistance 39 (60.0) 91 (38.7) 10 (43.5) 4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)	>\$160,000	0 (0.0)	23 (9.7)	1(4.3)
(N=322) No 24 (39.3) 10 (4.2) 0 (0.0) Yes 37 (60.7) 228 (95.8) 23 (100.0) In the past 6 months, has your HH received any public assistance? (%) (N=3223)**** 1 (1.5) 47 (20.0) 7 (30.4) No assistance 12 (18.5) 89 (37.9) 6 (26.1) 2 - 3 types of assistance 39 (60.0) 91 (38.7) 10 (43.5) 4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)	Prefer not to answer	20 (30.3)	30 (12.7)	3 (13.0)
No 24 (39.3) 10 (4.2) 0 (0.0) Yes 37 (60.7) 228 (95.8) 23 (100.0) In the past 6 months, has your HH received any public assistance? (%) (N=3223)**** 1 (1.5) 47 (20.0) 7 (30.4) No assistance 12 (18.5) 89 (37.9) 6 (26.1) 2 - 3 types of assistance 39 (60.0) 91 (38.7) 10 (43.5) 4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)				
Yes 37 (60.7) 228 (95.8) 23 (100.0) In the past 6 months, has your HH received any public assistance? (%) (N=3223)**** 1 (1.5) 47 (20.0) 7 (30.4) No assistance 1 (1.5) 47 (20.0) 7 (30.4) 1 type of assistance 12 (18.5) 89 (37.9) 6 (26.1) 2 - 3 types of assistance 39 (60.0) 91 (38.7) 10 (43.5) 4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)				
In the past 6 months, has your HH received any public assistance? (%) (N=3223)**** 1 (1.5) 47 (20.0) 7 (30.4) No assistance 1 (1.5) 47 (20.0) 7 (30.4) 1 type of assistance 12 (18.5) 89 (37.9) 6 (26.1) 2 - 3 types of assistance 39 (60.0) 91 (38.7) 10 (43.5) 4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)		· · ·	. ,	
assistance? (%) (N=3223)****No assistance1 (1.5)1 type of assistance1 (1.5)2 - 3 types of assistance39 (60.0)4 - 5 types of assistance13 (20.0)8 (3.4)0 (0.0)		37 (60.7)	228 (95.8)	23 (100.0)
No assistance1 (1.5)47 (20.0)7 (30.4)1 type of assistance12 (18.5)89 (37.9)6 (26.1)2 - 3 types of assistance39 (60.0)91 (38.7)10 (43.5)4 - 5 types of assistance13 (20.0)8 (3.4)0 (0.0)				
1 type of assistance12 (18.5)89 (37.9)6 (26.1)2 - 3 types of assistance39 (60.0)91 (38.7)10 (43.5)4 - 5 types of assistance13 (20.0)8 (3.4)0 (0.0)				
2 - 3 types of assistance 39 (60.0) 91 (38.7) 10 (43.5) 4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)				
4 - 5 types of assistance 13 (20.0) 8 (3.4) 0 (0.0)			. ,	. ,
				• •
		13 (20.0)	8 (3.4)	0 (0.0)

¹Respondents excluded if missing response for a certain variable

*Among adult respondents only.


**Among individuals that responded "Yes" to working outside the home during the "stay at home" order.

***Symptoms include cough, sore throat, chills, shortness of breath, fever, body aches, nausea, loss of smell, loss of appetite, fatigue, headache.


*****Assistances include: WIC, TANF, SSI, Public medical insurance, unemployment insurance, COVID-19 related stimulus payment, Food pantry/Food basket support.


Matias and Fulcher et al. SARS-CoV-2 Antibody Seroprevalence in Holyoke, MA





Matias and Fulcher et al. SARS-CoV-2 Antibody Seroprevalence in Holyoke, MA





*n refers to the number of individuals that tested positive. N refers to the total number of individuals that responded "Yes" to the given question.

**being contact-traced refers to individuals that reported being contacted by public health agencies in Massachusetts and told that they were in contact with a person with COVID-19.

*Three individuals that did not remember their test results and four individuals that had not received their test results at the time of the survey. Results are for people that reported getting at least one test.